Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Hedge fund of funds post best results in four years, but investors still pull out - hedge fund news, week 02

Saturday, January 11, 2014

In the week ending 10 January, 2014, the HFRI Fund of Hedge Funds Index was up 1.2% in December (+8.7% in 2013), its highest return in four years; but despite the rebound in performance, according to eVestment, assets in funds of hedge funds are at an all-time low relative to their single manager counterparts.

Twins Cameron and Tyler Winklevoss are backing a new hedge fund run by Aalap Mahadevia called Briarwood Chase Management; Balter Capital Management’s new Long/Short Equity Fund was launched with $100m from Summer Road, a New York-based family office; Gregg Hymowitz raised $600m to back funds run by shareholder activists; and West Face Capital opened a $553m credit fund to finance companies.

Eagle River Asset, which closed down after its backer FRM Holdings pulled its investment, will return most of its investors money this month; JP Morgan A. M. is set to liquidate its alternative UCITS commodities fund next month following a drop in assets;

The HFRX Global Hedge Fund Index gained +0.56% in December (+6.72% in 2013; The Greenwich Global Hedge Fund Index rose +0.94% (+8.99% in 2013 YTD); The Lyxor Hedge Fund Indices gained 1.15% (+7.0% in 2013; The Bloomberg Hedge Funds Aggregate Index expanded by 0.1% (+7.4 in 2013 YTD); The Barclay Hedge Fund Index went up 1.28% (+11.28% in 2013; The Credit Suisse Liquid Alternative Beta Index was up 0.48 (+7.35% in 2013); The IQ Hedge Composite Beta Index up returned 0.39% (+3.62% in 2013; The HFRU Equity Hedge Index up gained 0.43% in (+8.67% in 2013; And the UCITS Alternative Ind......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for